TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study

Neurology

Volumn 53, Issue 3, 1999, Pages 457-465

  Arnason, Barry G W ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; HYBRID PROTEIN; IMMUNOGLOBULIN G; INTERFERON; LENERCEPT; PROTEIN P55; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ALLERGIC ENCEPHALOMYELITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; FEMALE; HEADACHE; HOT FLUSH; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NAUSEA; OLIGODENDROGLIA; PATHOGENESIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033546665     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.3.457     Document Type: Article

References (29)

1. Hofman FM, Hinton DR, Johnson K, Merrill JE. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 1989;170:607-612.
2. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. 1988;23:339-346.
3. Selmaj KW, Farooq M, Norton WT, Raine CS, Brosnan CF. Proliferation of astrocytes in vitro in response to cytokine: a primary role for tumor necrosis factor. J Immunol 1990;144: 129-135.
4. Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease and disease progression in patients with multiple sclerosis. N Engl J Med 1991;325:467-472.
5. Maimone D, Gregory S, Arnason BGW, Reder AT. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol 1991;32:67-74.
6. Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 1988;78:318-323.
7. Rieckmann P, Albrecht M, Kitze B, et al. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology 1994;44:1523-1526.
8. Rieckmann P, Albrecht M, Kitze B, et al. Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 1995;37:82-88.
9. Kuroda Y, Shimamoto Y. Human tumor necrosis factor-alpha augments experimental allergic encephalomyelitis in rats. J Neuroimmunol 1991;34:159-164.
10. Ruddle NH, Bergman CM, McGrath KM, et al. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med 1990;172: 1193-1200.
11. Selmaj K, Raine CS, Cross AH. Anti-tumor necrosis factor abrogates autoimmune demyelination. Ann Neurol 1991;30: 694-700.
12. Baker D, Butler D, Scallon BJ, O'Neill JK, Turk JL, Feldmann M. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur J Immunol 1994;24:2040-2048.
13. Klinkert WE, Kojima K, Lesslauer W, Rinner W, Lassmann H, Wekerle H. TNF-alpha receptor fusion protein prevents experimental autoimmune encephalomyelitis and demyelination in Lewis rats: an overview. J Neuroimmunol 1997;72: 163-168.
14. Ashkenazi A, Marsters SA, Capon DJ, et al. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesion. Proc Natl Acad Sci USA 1991;88:10535-10539.
15. Lesslauer W, Tabuchi H, Gentz R, et al. Recombinant soluble TNF receptor proteins protect mice from LPS-induced lethality. Eur J Immunol 1991;21:2883-2886.
16. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 1996;39:6-16.
17. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
18. Paty DW, Li DKB, the UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667.
19. Sipe JC, Knobler RL, Braheny SL, Rice GPA, Panitch HS, Oldstone MBA. A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology 1984;34:1368-1372.
20. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352:1498-1504.
21. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
22. Bauer P. Multiple testing in clinical trials. Stat Med 1991;10: 871-890.
23. Cox DR, Oakes D. Analysis of survival data. London: Chapman and Hall, 1984.
24. Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Stat 1982;10:1100-1120.
25. Van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996;47:1531-1534.
26. Liu J, Marino MW, Wong G, et al. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med 1998;4:78-83.
27. Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987;1:893-895.
28. Berger S, Chandra R, Balló H, Hildebrand R, Stutte HJ. Immune complexes are potent inhibitors of interleukin-12 secretion by human monocytes. Eur J Immunol 1997;27:2994-3000.
29. Sanders O, Ran R, van Riel P, et al. Neutralization of TNF by lenercept (TNFR55-IgG, Ro 45-2081) in patients with rheumatoid arthritis treated for 3 months: results of a European phase II trial. Arthritis Rheum 1996;39(suppl 9):242.